Tectonic Therapeutic, INC

Tectonic Therapeutic has successfully completed patient enrollment for its Phase 2 APEX trial of TX45 in PH-HFpEF patients, with topline results anticipated in early Q1 2027.

Tectonic Therapeutic has appointed veteran biotechnology investment banker Jessica Chutter to its Board of Directors, effective June 8, 2026.

Tectonic Therapeutic announced its fourth quarter and full year 2025 financial results, highlighting positive clinical trial data for TX45 and advancement of TX2100 into Phase 1a.

Tectonic Therapeutic announced the appointment of Dr. Franois Nader as its new independent Board Chair, effective April 1, 2026, alongside an update on its clinical-stage HHT therapy, TX2100.

Tectonic Therapeutic announced positive Phase 1b TX45 data, progress on its pipeline, and a cash runway into Q4 2028, alongside its third-quarter 2025 financial results.

Tectonic Therapeutic announced positive topline results from its Phase 1b Part B clinical trial for TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF).

Tectonic Therapeutics, Inc. reported a net loss of $25.2 million for the first quarter of 2026, with research and development expenses increasing significantly.

Tectonic Therapeutic reports increased cash reserves and positive clinical trial data for TX45, despite ongoing net losses and rising R&D expenses in its Q3 2025 filing.

Tectonic Therapeutic, Inc. reports significant progress in its TX45 and TX2100 clinical programs, bolstered by a $173.1 million private placement, despite ongoing net losses.

Tectonic Therapeutic, a clinical-stage biotechnology company, announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and financial position.

Tectonic Therapeutic, following its merger with AVROBIO, reports a net loss of $17.7 million for the third quarter of 2024, while advancing its clinical programs.

Tectonic Therapeutic, following its merger with AVROBIO, reports a net loss of $27.9 million for the first six months of 2024, alongside a significant increase in cash reserves.

Tectonic Therapeutic, a clinical-stage biotechnology company, reported its 2025 annual financial results and provided updates on its lead product candidates, TX45 and TX2100, including ongoing clinical trials and future milestones.

Tectonic Therapeutic, a clinical-stage biotechnology company, announces its full year 2024 financial results and provides an update on its clinical development programs, including TX45 for pulmonary hypertension and TX2100 for hereditary hemorrhagic telangiectasia.

AVROBIO has ceased development of its gene therapy programs and is pursuing strategic options, including a merger with Tectonic Therapeutics, to maximize shareholder value.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, executed a stock transaction under a pre-arranged Rule 10b5-1 trading plan.

Tectonic Therapeutic, Inc. director Timothy A. Springer acquired stock options for 10,200 shares of common stock.

Praveen P. Tipirneni, a Director at Tectonic Therapeutic, Inc., acquired 10,200 stock options with an exercise price of $28.56.

Phillip B. Donenberg, a Director at Tectonic Therapeutic, Inc., acquired 10,200 stock options.

Stefan Vitorovic, a Director at Tectonic Therapeutic, Inc., has acquired stock options for 10,200 shares of common stock.

Tectonic Therapeutic, Inc. reports the grant of stock options to Director Jessica Caroline Chutter.

Tectonic Therapeutic, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 8, 2026, to address director elections, auditor ratification, and executive compensation.

Tectonic Therapeutic, Inc. announces its 2025 Annual Meeting and provides instructions for shareholders to vote on key proposals.

Tectonic Therapeutic announces its 2025 Annual Meeting of Stockholders to be held virtually on June 6, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory votes.

Tectonic Therapeutic is registering for resale up to 3,689,465 shares of its common stock following a recent \$185 million private placement.

Tectonic Therapeutic registers for resale up to 2.97 million shares of its common stock by selling stockholders following its recent merger with AVROBIO.

Timothy A. Springer and TAS Partners LLC, along with Chafen Lu, have significantly increased their beneficial ownership in Tectonic Therapeutic, Inc. to 31.5% through recent share purchases.

A recent SEC filing reveals that Polaris Partners IX, L.P. has significantly reduced its beneficial ownership in Tectonic Therapeutic, Inc. by selling 500,000 shares, while Timothy A. Springer and TAS Partners LLC acquired the same block of shares.

Vida Ventures II, LLC and Vida Ventures II-A, LLC have reported a complete divestment of their beneficial ownership in Tectonic Therapeutic, Inc. through a series of distributions and market sales.

Tectonic Therapeutic, Inc. announced the successful closing of a $185 million private placement of common stock, significantly increasing the beneficial ownership of key insiders, including Dr. Timothy A. Springer, to 29.2%.

Vida Ventures II, LLC and its affiliates have filed an amended Schedule 13D, reporting a decrease in their aggregate beneficial ownership of Tectonic Therapeutic, Inc. to 5.6% due to dilution from the Issuer's recent private placement.

Polaris Partners and affiliated entities, including director Terrance McGuire, have filed an amended Schedule 13D for Tectonic Therapeutic, Inc., updating their beneficial ownership percentage due to dilution from the Issuer's recent private placement.

TCG Crossover Funds and Chen Yu have disclosed a combined 6.2% beneficial ownership stake in Tectonic Therapeutic, Inc. common stock.

Aberdeen Group plc and its subsidiary abrdn Inc. have reported a 6.10% beneficial ownership stake in Tectonic Therapeutic, Inc. as of December 31, 2025.

EcoR1 Capital, LLC and its affiliates report 0% beneficial ownership in Tectonic Therapeutic, Inc. common stock.

Deep Track Capital and its affiliates have reported zero beneficial ownership in Tectonic Therapeutic, Inc., indicating a complete divestment of their prior stake.

EcoR1 Capital, LLC and its control person Oleg Nodelman have filed an amended Schedule 13G, disclosing a beneficial ownership of 5.0% in Tectonic Therapeutic, Inc.'s common stock as of March 31, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a 15.0% beneficial ownership stake in Tectonic Therapeutic Inc. as of March 31, 2025.